How Early Detection & Diagnostic Products Will Shape the Future of Healthcare

Life Sciences, Clinical Trials, Pharmaceutical, Medical Device, Healthcare, Medical Device Diagnostics,
  • Monday, November 14, 2022

The clinical trial pipeline of early detection and diagnostic products is rapidly expanding. Since healthcare can often be better characterized as “sick care,” this expansion holds great promise for intersecting with patients earlier in their disease progression to improve outcomes. However, the historic utilization of currently available screening tools indicates significant barriers to the greater adoption of new diagnostic methods and products.

What impacts the diagnostic process within healthcare? How can the lessons learned from these barriers inform clinical trial design to reduce the gap from discovery to utilization and payor coverage?

In this webinar, the featured speakers will explore the barriers between healthcare and new early detection and diagnostic methods and how the strategies used to overcome such challenges can be applied to clinical research, ultimately translating to a more patient-centered trial experience and faster adoption of life-improving and lifesaving tools.

Register for this Elligo Elite Learning Series webinar for expert insights and an engaging discussion on how early detection and diagnostic products will shape the future of healthcare. 

Speakers

http://Faith%20Holmes,%20Elligo%20Health%20Research

Faith Holmes, MD, Medical Director, Senior Vice President of Medical Affairs, Elligo

Faith Holmes, MD, brings more than 30 years of experience in direct patient care, and 11 years of medical practice management to her role as Elligo’s Senior Vice President of Medical Affairs. Her unique perspective plays an important part in building the company’s network of Research Ready physician practices and preparing them to conduct research. Holmes’ rich perspective — including experience in family medicine, hospice and palliative medicine that spans solo practice and single specialty and multispecialty group practices — allows her to build rapport with study managers, site staff and investigators, and provide medical and scientific knowledge to support future growth. Holmes has served as the Principal Investigator for interventional, diagnostic device and observational trials in several therapeutic indications in Elligo’s eSolutions model and at the Elligo Clinical Research Center. She earned her Bachelor of Science degree in Chemistry and Biology from Trevecca University, her Doctor of Medicine degree from ORU School of Medicine, and is board certified in family medicine and hospice and palliative medicine.

Message Presenter
http://Dawn%20Sauro,%20Elligo

Dawn Sauro, Executive Vice President, Research Strategy, Elligo

Dawn Sauro has 30+ years of drug and device development experience, including working for sites, sponsors and CROs. She has experience across a broad spectrum of therapeutic areas, but her main area of expertise is in hematology and oncology. Having led several successful hematology/oncology development programs from First-in-Human through successful registration, she brings this expertise in delivery to help sponsors drive results.

Prior to joining Elligo, Dawn was Chief Development Officer at Clinipace Clinical Research where she grew the organization to be a trusted partner for oncology programs, over 80 percent of the portfolio at Clinipace was in oncology. Prior roles also include President, Development Innovations at Sarah Cannon and Sr. Vice President and General Manager, Hematology/Oncology at inVentiv Health (now Syneos).

Message Presenter

Who Should Attend?

Attendees from the following industries:

  • Pharma, Biotech, Medical Device
  • CROs

Relevant areas:

  • Early Detection
  • Diagnostics
  • Oncology

What You Will Learn

Attendees will learn:

  • The historic utilization of currently available screening tools within the healthcare setting
  • What impacts the diagnostic process within healthcare from the practicing physician and patient perspective
  • Possible strategies for improving the utilization of new early detection and diagnostic methods
  • How these lessons can inform clinical trial design as well as decisions around investigator collaborations in clinical trials

Xtalks Partner

Elligo Health Research®

Elligo Health Research accelerates clinical trials through healthcare with access to over 150 million known patients and their HIPAA-compliant healthcare data, our IntElligo® Research Stack technology, and our PatientSelect identification and engagement model. Coupled with the largest Known Patient Access Network, Elligo’s Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, we accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account